Understanding how different proteins affect bone growth for low bone mass
Different Roles for Colony Stimulating Factor 1 Isoforms in Anabolic Therapy for Low Bone Mass
This project explores how two forms of a protein called CSF1 influence bone-building treatments for people with low bone density.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11111326 on NIH RePORTER |
What this research studies
Our bones constantly rebuild themselves, and treatments for low bone mass aim to boost this process. This project looks at how a protein called CSF1, released by bone-forming cells, talks to bone-resorbing cells to encourage new bone growth. We've found that two different versions of CSF1 have opposite effects on how well bone-building treatments work. One version seems to help bone growth, while the other appears to hinder it. By understanding these differences, we hope to find new ways to make treatments for low bone density more effective.
Who could benefit from this research
Good fit: This foundational research does not directly involve patients, but future clinical applications would target individuals with low bone mass or osteoporosis.
Not a fit: Patients not experiencing low bone mass or conditions requiring anabolic bone therapy would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to improved treatments that better stimulate bone formation for individuals with conditions like osteoporosis.
How similar studies have performed: While the general approach of understanding bone cell communication is established, the specific roles of these two CSF1 isoforms in anabolic therapy represent a novel area of investigation.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Insogna, Karl Leonard — Yale University
- Study coordinator: Insogna, Karl Leonard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.